Abstract
The objective of the study was to investigate the effect of genetic polymorphisms in glutathione S-transferases (GST) on the survival of acute myeloid leukaemia patients receiving adriamycin induction therapy. A total of 89 patients were included in the study. Patients who carried at least one GSTM1 allele had trend towards a better survival (mortality rate ratio (RR) 0.588; 95% CI 0.334-1.036) than GSTM1*0/0 patients. However, at low accumulated adriamycin dose, GSTM1*0/0 cases had a better survival than people expressing the gene (RR=6.1; 95% CI=1.2-11.0). The GSTT1 and GSTP1 genotype did not influence the survival in any of the groups.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Adult
-
Aged
-
Aged, 80 and over
-
Alleles
-
Antibiotics, Antineoplastic / therapeutic use
-
Antimetabolites, Antineoplastic / therapeutic use
-
Cytarabine / therapeutic use
-
Doxorubicin / therapeutic use
-
Female
-
Glutathione S-Transferase pi
-
Glutathione Transferase / genetics*
-
Humans
-
Isoenzymes / genetics
-
Leukemia, Myeloid / drug therapy*
-
Leukemia, Myeloid / genetics
-
Leukemia, Myeloid / mortality
-
Male
-
Middle Aged
-
Survival Analysis
-
Survival Rate
-
Treatment Outcome
Substances
-
Antibiotics, Antineoplastic
-
Antimetabolites, Antineoplastic
-
Isoenzymes
-
Cytarabine
-
Doxorubicin
-
glutathione S-transferase T1
-
GSTP1 protein, human
-
Glutathione S-Transferase pi
-
Glutathione Transferase
-
glutathione S-transferase M1